Due to many adverse effects of conventional chemotherapy, novel methods of targeting drugs to cancer cells are being investigated. Nanosize carriers are a suitable platform for this specific delivery. Herein, we evaluated the long-term stability of the naturally found protein nanocarrier apoferritin (Apo) with encapsulated doxorubicin (Dox). The encapsulation was performed using Apo's ability to disassemble reversibly into its subunits at low pH (2.7) and reassemble in neutral pH (7.2), physically entrapping drug molecules in its cavity (creating ApoDox). In this study, ApoDox was prepared in water and phosphate-buffered saline and stored for 12 weeks in various conditions (-20°C, 4°C, 20°C, and 37°C in dark, and 4°C and 20°C under ambient light). During storage, a very low amount of prematurely released drug molecules were detected (maximum of 7.5% for ApoDox prepared in PBS and 4.4% for ApoDox prepared in water). Fourier-transform infrared spectra revealed no significant differences in any of the samples after storage. Most of the ApoDox prepared in phosphate-buffered saline and ApoDox prepared in water and stored at -20°C formed very large aggregates (up to 487% of original size). Only ApoDox prepared in water and stored at 4°C showed no significant increase in size or shape. Although this storage caused slower internalization to LNCaP prostate cancer cells, ApoDox (2.5 μM of Dox) still retained its ability to inhibit completely the growth of 1.5×104 LNCaP cells after 72 hours. ApoDox stored at 20°C and 37°C in water was not able to deliver Dox inside the nucleus, and thus did not inhibit the growth of the LNCaP cells. Overall, our study demonstrates that ApoDox has very good stability over the course of 12 weeks when stored properly (at 4°C), and is thus suitable for use as a nanocarrier in the specific delivery of anticancer drugs to patients.

Department of Biochemistry Faculty of Science Charles University Prague Czech Republic

Department of Chemistry and Biochemistry Mendel University in Brno

Department of Chemistry and Biochemistry Mendel University in Brno; Central European Institute of Technology Brno University of Technology Brno

Department of Pediatric Hematology and Oncology 2nd Faculty of Medicine University Hospital Motol Charles University

Zobrazit více v PubMed

Dimarco A, Gaetani M, Scarpinato B. Adriamycin (NSC-123, 127): a new antibiotic with antitumor activity. Cancer Chemother Rep. 1969;53(1):33–37. PubMed

Pilco-Ferreto N, Calaf GM. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int J Oncol. 2016;49(2):753–762. PubMed

Lv LX, An XM, Li HY, Ma LX. Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells. Oncol Lett. 2016;11(2):1161–1166. PubMed PMC

Shang C, Guo Y, Zhang H, Xue YX. Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma. Cancer Chemother Pharmacol. 2016;77(3):507–513. PubMed

Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1B and randomised phase 2 trial. Lancet. 2016;388(10043):488–497. PubMed PMC

Bürkle C, Borchmann P. Diagnostik und Therapie des Hodgkin-Lymphoms [Diagnosis and treatment of Hodgkin lymphoma] Onkologe. 2016;22(8):603–616. German.

Agudelo D, Bourassa P, Bérubé G, Tajmir-Riahi HA. Review on the binding of anticancer drug doxorubicin with DNA and tRNA: structural models and antitumor activity. J Photochem Photobiol B Biol. 2016;158:274–279. PubMed

Kumar A, Ehrenshaft M, Tokar EJ, Mason RP, Sinha BK. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells. Biochim Biophys Acta. 2016;1860(7):1519–1527. PubMed PMC

Agustini FD, Arozal W, Louisa M, et al. Cardioprotection mechanism of mangiferin on doxorubicin-induced rats: focus on intracellular calcium regulation. Pharm Biol. 2016;54(7):1289–1297. PubMed

Meredith AM, Dass CR. Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J Pharm Pharmacol. 2016;68(6):729–741. PubMed

World Health Organization WHO model list of essential medicines. 2015. [Accessed September 20, 2016]. Available from: http://www.who.int/medicines/publications/essentialmedicines/en.

Li XY, Wu MY, Pan LM, Shi JL. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor. Int J Nanomedicine. 2016;11:93–105. PubMed PMC

Mercurio V, Pirozzi F, Lazzarini E, et al. Models of heart failure based on the cardiotoxicity of anticancer drugs. J Card Fail. 2016;22(6):449–458. PubMed

Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157–170. PubMed

Xia CC, Yadav AK, Zhang K, et al. Synchrotron radiation (SR) diffraction enhanced imaging (DEI) of chronic glomerulonephritis (CGN) mode. J Xray Sci Technol. 2016;24(1):145–159. PubMed

Fanous I, Dillon P. Cancer treatment-related cardiac toxicity: prevention, assessment and management. Med Oncol. 2016;33(8):84. PubMed

Schuler MK, Gerdes S, West A, et al. Efficacy and safety of dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy: a retrospective study including 32 patients. BMC Cancer. 2016;16:619. PubMed PMC

Shaikh F, Dupuis LL, Alexander S, Gupta A, Mertens L, Nathan PC. Cardioprotection and second malignant neoplasms associated with dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and meta-analysis. J Natl Cancer Inst. 2016;108(4):djv357. PubMed

Luhmann T, Meinel L. Nanotransporters for drug delivery. Curr Opin Biotechnol. 2016;39:35–40. PubMed

Maeda H, Tsukigawa K, Fang J. A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy problems, solutions, and prospects. Microcirculation. 2016;23(3):173–182. PubMed

Dostalova S, Cerna T, Hynek D, et al. Site-directed conjugation of antibodies to apoferritin nanocarrier for targeted drug delivery to prostate cancer cells. ACS Appl Mater Interfaces. 2016;8(23):14430–14441. PubMed

Tian DY, Wang WY, Li SP, Li XD, Sha ZL. A novel platform designed by Au core/inorganic shell structure conjugated onto MTX/LDH for chemo-photothermal therapy. Int J Pharm. 2016;505(1–2):96–106. PubMed

Jena SK, Sangamwar AT. Polymeric micelles of amphiphilic graft copolymer of α-tocopherol succinate-g-carboxymethyl chitosan for tamoxifen delivery: synthesis, characterization and in vivo pharmacokinetic study. Carbohydr Polym. 2016;151:1162–1174. PubMed

Lindqvist A, Friden M, Hammarlund-Udenaes M. Pharmacokinetic considerations of nanodelivery to the brain: using modeling and simulations to predict the outcome of liposomal formulations. Eur J Pharm Sci. 2016;92:173–182. PubMed

Agudelo D, Berube G, Tajmir-Riahi HA. An overview on the delivery of antitumor drug doxorubicin by carrier proteins. Int J Biol Macromol. 2016;88:354–360. PubMed

Alphandery E, Grand-Dewyse P, Lefevre R, Mandawala C, Durand-Dubief M. Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. Expert Rev Anticancer Ther. 2015;15(10):1233–1255. PubMed

Kim HS, Wainer IW. Simultaneous analysis of liposomal doxorubicin and doxorubicin using capillary electrophoresis and laser induced fluorescence. J Pharm Biomed Anal. 2010;52(3):372–376. PubMed PMC

Suk JS, Xu QG, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99(Pt A):28–51. PubMed PMC

Tmejova K, Hynek D, Kopel P, et al. Electrochemical behaviour of doxorubicin encapsulated in apoferritin. Int J Electrochem Sci. 2013;8(12):12658–12671.

Liang MM, Fan KL, Zhou M, et al. H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection. Proc Natl Acad Sci U S A. 2014;111(41):14900–14905. PubMed PMC

Cutrin JC, Crich SG, Burghelea D, Dastru W, Aime S. Curcumin/Gd loaded apoferritin: a novel “theranostic” agent to prevent hepatocellular damage in toxic induced acute hepatitis. Mol Pharm. 2013;10(5):2079–2085. PubMed

Zang J, Chen H, Guanghua Z, Wang F, Ren F. Ferritin cage for encapsulation and delivery of bioactive nutrients: from structure, property to applications. Crit Rev Food Sci Nutr. 2016 Mar;:16. Epub. PubMed

Crich SG, Cadenazzi M, Lanzardo S, et al. Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells. Nanoscale. 2015;7(15):6527–6533. PubMed

Blazkova I, Nguyen HV, Dostalova S, et al. Apoferritin modified magnetic particles as doxorubicin carriers for anticancer drug delivery. Int J Mol Sci. 2013;14(7):13391–13402. PubMed PMC

Bulvik BE, Berenshtein E, Meyron-Holtz EG, Konijn AM, Chevion M. Cardiac protection by preconditioning is generated via an iron-signal created by proteasomal degradation of iron proteins. PLoS One. 2012;7(11):e48947. PubMed PMC

Asano T, Komatsu M, Yamaguchi-Iwai Y, Ishikawa F, Mizushima N, Iwai K. Distinct mechanisms of ferritin delivery to lysosomes in iron-depleted and iron-replete cells. Mol Cell Biol. 2011;31(10):2040–2052. PubMed PMC

Smith JL. The physiological role of ferritin-like compounds in bacteria. Crit Rev Microbiol. 2004;30(3):173–185. PubMed

Gallois B, dEstaintot BL, Michaux MA, et al. X-ray structure of recombinant horse L-chain apoferritin at 2.0 angstrom resolution: implications for stability and function. J Biol Inorg Chem. 1997;2(3):360–367.

Haussler W. Structure and dynamics in apoferritin solutions with paracrystalline order. Chem Phys. 2003;292(2–3):425–434.

Kim M, Rho Y, Jin KS, et al. pH-dependent structures of ferritin and apoferritin in solution: disassembly and reassembly. Biomacromolecules. 2011;12(5):1629–1640. PubMed

Kilic MA, Ozlu E, Calis S. A novel protein-based anticancer drug encapsulating nanosphere: apoferritin-doxorubicin complex. J Biomed Nanotechnol. 2012;8(3):508–514. PubMed

Wood MJ, Irwin WJ, Scott DK. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid-chromatography. J Clin Pharm Ther. 1990;15(4):291–300. PubMed

Konecna R, Nguyen HV, Stanisavljevic M, et al. Doxorubicin encapsulation investigated by capillary electrophoresis with laser-induced fluorescence detection. Chromatographia. 2014;77(21–22):1469–1476.

Dai XW, Yue ZL, Eccleston ME, Swartling J, Slater NK, Kaminski CF. Fluorescence intensity and lifetime imaging of free and micellar-encapsulated doxorubicin in living cells. Nanomed Nanotechnol Biol Med. 2008;4(1):49–56. PubMed

Yang K, Luo HQ, Zeng M, Jiang YY, Li JM, Fu XL. Intracellular pH-triggered, targeted drug delivery to cancer cells by multifunctional envelope-type mesoporous silica nanocontainers. ACS Appl Mater Interfaces. 2015;7(31):17399–17407. PubMed

Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615–627. PubMed

Svenson S. Theranostics: are we there yet? Mol Pharm. 2013;10(3):848–856. PubMed

Appelbe OK, Zhang Q, Pelizzari CA, Weichselbaum RR, Kron SJ. Image-guided radiotherapy targets macromolecules through altering the tumor microenvironment. Mol Pharm. 2016;13(10):3457–3467. PubMed PMC

Liu T, Chao Y, Gao M, et al. Ultra-small MoS2 nanodots with rapid body clearance for photothermal cancer therapy. Nano Res. 2016;9(10):3003–3017.

Svenson S. Clinical translation of nanomedicines. Curr Opin Solid State Mater Sci. 2012;16(6):287–294.

Gratton SE, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008;105(33):11613–11618. PubMed PMC

Zamboni WC, Torchilin V, Patri AK, et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res. 2012;18(12):3229–3241. PubMed PMC

Stylianopoulos T, Jain RK. Design considerations for nanotherapeutics in oncology. Nanomed Nanotechnol Biol Med. 2015;11(8):1893–1907. PubMed PMC

Fülöp Z, Gref R, Loftsson T. A permeation method for detection of self-aggregation of doxorubicin in aqueous environment. Int J Pharm. 2013;454(1):559–561. PubMed

Righetti PG, Menozzi M, Gianazza E, Valentini L. Protolytic equilibria of doxorubicin as determined by isoelectric-focusing and electrophoretic titration curves. FEBS Lett. 1979;101(1):51–55. PubMed

Beijnen JH, Wiese G, Underberg WJ. Aspects of the chemical-stability of doxorubicin and seven other anthracyclines in acidic solution. Pharm Weekbl Sci. 1985;7(3):109–116. PubMed

Liu AY. Differential expression of cell surface molecules in prostate cancer cells. Cancer Res. 2000;60(13):3429–3434. PubMed

Norepinephrine transporter-derived homing peptides enable rapid endocytosis of drug delivery nanovehicles into neuroblastoma cells

An Investigation on the Electrochemical Behavior and Antibacterial and Cytotoxic Activity of Nickel Trithiocyanurate Complexes

Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin